Vertex Pharmaceuticals Incorporated
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
A Microneurography Study of NaV1.8 Inhibition in Healthy Adults
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 40
- Registration Number
- NCT06420765
- Locations
- π¬π§
MAC Clinical Research, Manchester, United Kingdom
A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 110
- Registration Number
- NCT06394167
- Locations
- πΊπΈ
ICON Lenexa, Lenexa, Kansas, United States
A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 42
- Registration Number
- NCT06392659
- Locations
- π¬π§
MAC Clinical Research, Manchester, United Kingdom
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of VX-407 in Healthy Participants
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 95
- Registration Number
- NCT06345755
- Locations
- πΊπΈ
ICON Lenexa, Lenexa, Kansas, United States
A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 48
- Registration Number
- NCT06336096
- Locations
- πΊπΈ
Celerion - Tempe, Tempe, Arizona, United States
A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 15
- Registration Number
- NCT06312787
- Locations
- πΊπΈ
Celerion - Lincoln, Lincoln, Nebraska, United States
A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 10
- Registration Number
- NCT06299696
- Locations
- πΊπΈ
Site 001, Woburn, Massachusetts, United States
A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 34
- Registration Number
- NCT06299709
- Locations
- πΊπΈ
Celerion, Inc., Tempe, Arizona, United States
A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 39
- Registration Number
- NCT06226454
- Locations
- πΊπΈ
ICON Salt Lake City, Salt Lake City, Utah, United States
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
- First Posted Date
- 2023-12-29
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 36
- Registration Number
- NCT06185764
- Locations
- π¨π¦
McGill University, Montreal, Canada
π¨π¦Altasciences Montreal, Mont-Royal, Canada
π¦πΊNeuroscience Clinical Trials Unit, Alfred Brain, Melbourne, Australia
Β© Copyright 2024. All Rights Reserved by MedPath